Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 26:14:1253319.
doi: 10.3389/fendo.2023.1253319. eCollection 2023.

Editorial: Neuroendocrine tumors: the road to precision medicine

Anna La Salvia  1 , Dario Giuffrida  2 , Roberta Modica  3
Affiliations
Editorial

Editorial: Neuroendocrine tumors: the road to precision medicine

Anna La Salvia et al. Front Endocrinol (Lausanne). .
No abstract available

Keywords: Merkel cell carcinoma; insulinoma; medullary thyroid carcinoma; neuroendocrine neoplasm (NEN); pancreas; personalized medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Neuroendocrine tumors: the road to precision medicine

References

    1. Colao A, de Nigris F, Modica R, Napoli C. Clinical epigenetics of neuroendocrine tumors: the road ahead. Front Endocrinol (Lausanne) (2020) 11:604341. doi: 10.3389/fendo.2020.604341 - DOI - PMC - PubMed
    1. Melone V, Salvati A, Palumbo D, Giurato G, Nassa G, Rizzo F, et al. . Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. J Transl Med (2022) 20(1):306. doi: 10.1186/s12967-022-03511-7 - DOI - PMC - PubMed
    1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol (2017) 3(10):1335–42. doi: 10.1001/jamaoncol.2017.0589 - DOI - PMC - PubMed
    1. La Salvia A, Modica R, Rossi RE, Spada F, Rinzivillo M, Panzuto F, et al. . Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists. Cancer Treat Rev (2023) 117:102560. doi: 10.1016/j.ctrv.2023.102560 - DOI - PubMed
    1. Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab (2022) 17(5):389–403. doi: 10.1080/17446651.2022.2099840 - DOI - PubMed

Publication types